Table 2.
Angiographic and Procedural characteristics.
| Overall population | IPTW population | |||||
|---|---|---|---|---|---|---|
| DP-DES | BP-DES | p value | DP-DES | BP-DES | p value | |
| n = 374 | n = 246 | n = 498 | n = 491 | |||
| Angiographic findings | ||||||
| Culprit lesion location | 0.074 | 0.109 | ||||
| LM | 63 (16.8) | 31 (12.6) | 74 (14.9) | 71 (14.5) | ||
| LAD | 160 (42.8) | 102 (41.5) | 216 (43.2) | 194 (39.4) | ||
| LCX | 41 (11.0) | 19 (7.7) | 54 (10.8) | 41 (8.3) | ||
| RCA | 110 (29.4) | 94 (38.2) | 155 (31.1) | 185 (37.7) | ||
| Culprit lesion TIMI flow grade, pre-PCI | 0.694 | 0.987 | ||||
| 0 | 209 (55.9) | 147 (59.8) | 289 (58.0) | 287 (58.4) | ||
| 1 | 33 (8.8) | 17 (6.9) | 41 (8.2) | 42 (8.6) | ||
| 2 | 60 (16.0) | 40 (16.3) | 75 (15.0) | 73 (14.8) | ||
| 3 | 72 (19.3) | 42 (17.1) | 94 (18.9) | 89 (18.2) | ||
| Culprit lesion TIMI flow grade, post-PCI | 0.120 | 0.975 | ||||
| 0 | 4 (1.1) | 3 (1.2) | 4 (0.9) | 3 (0.7) | ||
| 1 | 4 (1.1) | 9 (3.7) | 9 (1.8) | 10 (2.1) | ||
| 2 | 46 (12.3) | 36 (14.6) | 53 (10.6) | 52 (10.5) | ||
| 3 | 320 (85.6) | 198 (80.5) | 432 (86.7) | 426 (86.7) | ||
| Vessel disease | 0.483 | 0.183 | ||||
| 1-vessel disease | 76 (20.3) | 57 (23.2) | 110 (22.0) | 105 (21.5) | ||
| 2-vessel disease | 168 (44.9) | 99 (40.2) | 226 (45.3) | 199 (40.5) | ||
| 3-vessel disease | 130 (34.8) | 90 (36.6) | 163 (32.7) | 187 (38.1) | ||
| Multivessel disease | 298 (79.7) | 189 (76.8) | 0.398 | 389 (78.0) | 386 (78.6) | 0.748 |
| SYNTAX score, pre-PCI | 23.6 ± 11.0 | 22.3 ± 10.8 | 0.140 | 23.3 ± 10.8 | 23.2 ± 11.4 | 0.943 |
| SYNTAX score, post-PCI | 6.4 ± 8.2 | 6.2 ± 7.9 | 0.672 | 6.3 ± 7.8 | 6.5 ± 8.0 | 0.610 |
| Number of lesions | 2.3 ± 1.1 | 2.3 ± 1.2 | 0.849 | 2.3 ± 1.1 | 2.3 ± 1.1 | 0.769 |
| Non-culprit LM or proximal LAD involvement | 58 (15.5) | 39 (15.9) | 0.908 | 85 (17.1) | 78 (16.0) | 0.957 |
| Procedural characteristics | ||||||
| Access site | 0.222 | 0.497 | ||||
| Transradial approach | 311 (83.2) | 195 (79.3) | 414 (83.1) | 400 (81.4) | ||
| Transfemoral approach | 63 (16.8) | 51 (20.7) | 84 (16.9) | 91 (18.6) | ||
| Contrast volume, mL | 177.8 ± 88.5 | 184.8 ± 61.5 | 0.567 | 185.8 ± 100.8 | 186.0 ± 59.5 | 0.990 |
| Thrombus aspiration | 102 (27.3) | 92 (37.4) | 0.008 | 149 (29.9) | 148 (30.2) | 0.728 |
| Performed staged PCI | 38 (10.2) | 23 (9.4) | 0.932 | 48 (9.7) | 52 (10.6) | 0.790 |
| Timing of staged PCI, days | 4.0 (3.0–8.0) | 4.0 (2.0–9.0) | 0.696 | 4.0 (3.0–7.0) | 4.0 (2.0–9.0) | 0.730 |
| Number of used stent | 1.6 ± 0.9 | 1.5 ± 0.8 | 0.140 | 1.5 ± 0.8 | 1.5 ± 0.8 | 0.608 |
| Number of treated lesion | 1.5 ± 0.8 | 1.4 ± 0.7 | 0.104 | 1.5 ± 0.8 | 1.5 ± 0.7 | 0.433 |
| Maximal diameter of stents, mm | 3.2 ± 0.5 | 3.2 ± 0.4 | 0.561 | 3.2 ± 0.5 | 3.2 ± 0.4 | 0.174 |
| Length of stents, mm | 38.6 ± 24.4 | 37.2 ± 24.0 | 0.484 | 37.5 ± 23.1 | 37.5 ± 23.9 | 0.992 |
Data are n (%), mean ± standard deviation, or median (interquartile range).
BP-DES biodegradable polymer drug-eluting stent, DP-DES durable polymer drug-eluting stent, IPTW inverse probability of treatment weighting, LAD left anterior descending artery, LCX left circumflex artery, LM left main coronary artery, PCI percutaneous coronary intervention, RCA right coronary artery, SYNTAX Synergy between PCI with Taxus and Cardiac Surgery, TIMI thrombolysis in myocardial infarction.